Edge Wealth Management’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.53M Sell
87,000
-3,000
-3% -$73.7K 0.38% 31
2026
Q2
$1.93M Hold
90,000
– – 0.33% 32
2026
Q1
$1.25M Hold
90,000
– – 0.21% 34
2025
Q4
$1.46M Hold
90,000
– – 0.26% 32
2025
Q3
$1.35M Hold
90,000
– – 0.24% 34
2025
Q2
$1.05M Hold
90,000
– – 0.2% 35
2025
Q1
$669K Hold
90,000
– – 0.14% 41
2024
Q4
$540K Hold
90,000
– – 0.11% 44
2024
Q3
$461K Hold
90,000
– – 0.09% 51
2024
Q2
$326K Hold
90,000
– – 0.07% 57
2024
Q1
$289K Hold
90,000
– – 0.06% 62
2023
Q4
$441K Hold
90,000
– – 0.1% 52
2023
Q3
$490K Hold
90,000
– – 0.11% 51
2023
Q2
$604K Hold
90,000
– – 0.13% 49
2023
Q1
$795K Hold
90,000
– – 0.18% 45
2022
Q4
$670K Hold
90,000
– – 0.16% 48
2022
Q3
$660K Hold
90,000
– – 0.15% 47
2022
Q2
$728K Hold
90,000
– – 0.16% 45
2022
Q1
$1.25M Hold
90,000
– – 0.25% 45
2021
Q4
$2.52M Hold
90,000
– – 0.46% 38
2021
Q3
$3.06M Hold
90,000
– – 0.6% 36
2021
Q2
$3.68M Hold
90,000
– – 0.75% 32
2021
Q1
$3.62M Hold
90,000
– – 0.77% 33
2020
Q4
$5.3M Hold
90,000
– – 1.2% 27
2020
Q3
$4.38M Hold
90,000
– – 1.01% 35
2020
Q2
$4.35M Sell
90,000
-10,000
-10% -$365K 0.83% 35
2020
Q1
$2.72M Buy
+100,000
New +$2.79M 0.59% 43

Other funds holding ADPT

Edge Wealth Management's ADPT Position: Q3 2026 in Review

Edge Wealth Management reduced its Adaptive Biotechnologies (ADPT) stake by 3.3% in Q3 2026, selling an estimated $73.7K and leaving 87,000 shares worth $2.53M. The position accounts for 0.38% of the portfolio, ranked #31.

Edge Wealth Management first reported a position in ADPT in Q1 2020 and has held it in 27 quarters since. The position peaked at $5.3M in Q4 2020. 34 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Edge Wealth Management held 87,000 shares of Adaptive Biotechnologies worth $2.53M as of Q3 2026.
  • Edge Wealth Management sold 3,000 Adaptive Biotechnologies shares in Q3 2026, an estimated $73.7K.
  • Adaptive Biotechnologies made up 0.38% of Edge Wealth Management's portfolio in Q3 2026, its #31 holding.
  • Edge Wealth Management first reported a position in Adaptive Biotechnologies in Q1 2020 and has held it in 27 quarters since.
  • Edge Wealth Management's Adaptive Biotechnologies position peaked at $5.3M in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Edge Wealth Management's 13F filing for Q3 2026, filed 13 Oct 2026.